PCSK9 increases LDL cholesterol and ApoB by promoting LDL receptor degradation.

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a central regulator of cholesterol metabolism, specifically controlling the density of low-density lipoprotein receptors (LDLR) on the surface of liver cells. The claim that PCSK9 increases receptor turnover, reduces clearance, and raises cholesterol markers is strongly supported by high-quality genetic and clinical evidence.

Mechanistic explanations

PCSK9 functions by modulating the lifecycle of the LDLR. Under normal conditions, the LDLR binds to LDL particles, internalizes them via endocytosis, releases the particles in the acidic environment of the endosome, and then recycles back to the cell surface to clear more particles.

• Receptor Rerouting: PCSK9 binds to the EGF-A domain of the LDLR. This binding prevents the receptor from undergoing a conformational change necessary for recycling.
• Lysosomal Degradation: Instead of returning to the surface, the PCSK9-LDLR complex is diverted to the late endosomes and lysosomes where the receptor is degraded. This increases the "turnover" of receptors by shifting them from a recycling pathway to a destruction pathway.
• Surface Depletion: This degradation reduces the total pool of functional receptors available on the hepatocyte membrane, directly impairing the liver's ability to clear circulating LDL particles.

Clinical evidence and markers

The impact of PCSK9 on lipid markers is validated through both loss-of-function (LoF) genetic variants and pharmacological inhibition studies.

• LDL and ApoB Elevation: High levels of PCSK9 activity lead to reduced fractional catabolic rates (FCR) of LDL particles. Because each LDL particle contains exactly one molecule of apolipoprotein B (ApoB), the reduction in clearance causes a simultaneous rise in both LDL-C and total ApoB concentrations.
• Genetic Evidence: Carriers of PCSK9 LoF variants, such as rs11591147 (R46L), consistently exhibit approximately 19 mg/dL (0.5 mmol/L) lower LDL-C levels compared to non-carriers, demonstrating that lower PCSK9 activity leads to lower circulating lipids.
• Pharmacological Evidence: Monoclonal antibodies targeting PCSK9 (PCSK9 inhibitors) reduce LDL-C by 50-60% by preventing the degradation of LDLR, thereby dramatically increasing the hepatic clearance rate of LDL and ApoB.

Bottom line

PCSK9 directly raises LDL cholesterol and ApoB levels by binding to hepatic LDL receptors and rerouting them for lysosomal degradation. This process reduces the number of receptors available for clearance, a mechanism confirmed by both genetic studies and the therapeutic effectiveness of PCSK9 inhibitors.